Artiva Biotherapeutics (NASDAQ:ARTV) Upgraded to “Buy” at HC Wainwright

HC Wainwright upgraded shares of Artiva Biotherapeutics (NASDAQ:ARTV) to a buy rating in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm currently has $12.00 target price on the stock. HC Wainwright also issued estimates for Artiva Biotherapeutics’ Q2 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.04) EPS, FY2026 earnings at ($4.09) EPS, FY2027 earnings at ($1.64) EPS, FY2028 earnings at ($1.03) EPS and FY2029 earnings at ($0.63) EPS.

Several other research firms also recently weighed in on ARTV. Wedbush reiterated an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Tuesday, March 25th. Cantor Fitzgerald reduced their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 25th. Finally, Needham & Company LLC reduced their price objective on Artiva Biotherapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, May 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Artiva Biotherapeutics has an average rating of “Buy” and an average price target of $17.80.

Artiva Biotherapeutics Trading Down 3.4%

NASDAQ ARTV opened at $1.98 on Wednesday. The business’s 50-day moving average price is $2.11 and its 200 day moving average price is $5.31. Artiva Biotherapeutics has a twelve month low of $1.78 and a twelve month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.15). As a group, research analysts anticipate that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several hedge funds and other institutional investors have recently modified their holdings of ARTV. Deutsche Bank AG purchased a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at about $216,000. Norges Bank purchased a new stake in shares of Artiva Biotherapeutics during the 4th quarter valued at about $302,000. BNP Paribas Financial Markets raised its holdings in shares of Artiva Biotherapeutics by 262.1% during the 4th quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company’s stock valued at $100,000 after buying an additional 7,151 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Artiva Biotherapeutics by 250.7% during the 4th quarter. JPMorgan Chase & Co. now owns 37,619 shares of the company’s stock valued at $379,000 after buying an additional 26,893 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Artiva Biotherapeutics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock valued at $3,184,000 after buying an additional 6,828 shares during the period.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.